Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GAGE: Obinutuzumab 1000 mg vs 2000 mg in CLL
NCT01414205Phase 2Completed
- Sponsor
- Genentech
- Start
- Oct 2011
- Primary completion
- Mar 2013
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of obinutuzumab in chronic lymphocytic leukemia (CLL), sponsored by Genentech. Started Oct 2011; status: completed.
02
Drugs
obinutuzumab
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT01414205.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01414205.